# Royalty Pharma plc (RPRX) FY2026 Q1 P&L / Income Statement

- Company: Royalty Pharma plc (RPRX)
- Period: 2026-01-01 to 2026-03-31
- Filing: Q1 FY2026 10-Q, filed 2026-05-06, accession number 0001802768-26-000009
- Page: https://plicit.ai/financials/rprx/fy2026-q1-income-statement
- Chart image: https://plicit.ai/charts/rprx-fy2026-q1-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-01-01 through 2026-03-31. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total income and other revenues**: 630,576,000 US dollars
- **Total operating expense, net**: 67,538,000 US dollars
- **Operating income**: 563,038,000 US dollars
- **Total other expense, net**: negative 94,782,000 US dollars
- **Consolidated net income before tax**: 468,256,000 US dollars
- **Income tax expense**: 0 US dollars
- **Consolidated net income**: 468,256,000 US dollars
- **Income from financial royalty assets**: 594,992,000 US dollars
- **Other royalty income and revenues**: 35,584,000 US dollars
- **Provision for changes in expected cash flows from financial royalty assets**: negative 197,485,000 US dollars
- **Provision for credit losses on unfunded commitments**: negative 3,700,000 US dollars
- **Research and development funding expense**: 39,790,000 US dollars
- **General and administrative expenses (includes $122,292 and $703 of share-based compensation expense for the three months ended March 31, 2026 and 2025, respectively; see Note 4)**: 159,490,000 US dollars
- **Financial royalty asset impairment**: 69,443,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to Royalty Pharma plc: $294.69 M; to noncontrolling interests: $173.57 M.